BridgeMD
Contribution of an antiviral drug (Valaciclovir) in the treatment of generalized periodontitis (stage III or IV and grade A, B or C)
EU CTIS ID: 2022-501957-35-00
What this study is testing
Compare the efficacy of antiviral treatment (valaciclovir) with conventional non-surgical treatment (scalling, root surfacing) to conventional treatment with a placebo for generalized periodontitis (stage III or IV and grade A, B or C). This efficacy will be evaluated 28 days after the end of antiviral treatment and 2 months after root surfacing, during the periodontal re-evaluation visit
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Age ≥ 18 years
- Diagnosis of periodontitis induced by bacterial biofilms of dental plaque, generalized, stage III or IV and grade A, B or C
- Patients of childbearing age will need to use an effective method of contraception for the duration of their study participation
- Signature of informed consent
- Membership of a social security scheme
You likely can't join if
- Necrotizing periodontitis
- Renal failure (creatinine clearance < 60 ml/min)
- Systemic antibiotic therapy or any medication affecting the periodontal environment (systemic antibiotics, antiepileptics, immunosuppressants, calcium inhibitors) taken within 3 months of inclusion
- Nephrotoxic medications (aminoglycosides, organoplatines, iodized contrast agents, methotrexate, pentamidine, foscarnet, ciclosporine and tacrolimus)
- Hypersensitivity to valaciclovir, aciclovir or one of the excipients
- History of DRESS syndrome under valaciclovir treatment
See the full eligibility criteria
- Age ≥ 18 years
- Diagnosis of periodontitis induced by bacterial biofilms of dental plaque, generalized, stage III or IV and grade A, B or C
- Patients of childbearing age will need to use an effective method of contraception for the duration of their study participation
- Signature of informed consent
- Membership of a social security scheme
- Necrotizing periodontitis
- Renal failure (creatinine clearance < 60 ml/min)
- Systemic antibiotic therapy or any medication affecting the periodontal environment (systemic antibiotics, antiepileptics, immunosuppressants, calcium inhibitors) taken within 3 months of inclusion
- Nephrotoxic medications (aminoglycosides, organoplatines, iodized contrast agents, methotrexate, pentamidine, foscarnet, ciclosporine and tacrolimus)
- Hypersensitivity to valaciclovir, aciclovir or one of the excipients
- History of DRESS syndrome under valaciclovir treatment
- Pathologies requiring prophylactic antibiotic therapy (which may influence treatment)
- Non-surgical periodontal treatment completed within 6 months prior to inclusion
- Patients with enhanced protection, namely lactating women, persons deprived of liberty by judicial or administrative decision, persons over 18 under legal protection
- Patients who do not accept conventional therapy (gingival debridement not covered by the social security system) performed in each centre
- Periodontitis as a direct manifestation of systemic diseases
- Major systemic pathologies (diabetes, HIV, cancers, immunocompromised patients)
- Negative serology for EBV: a blood test will be performed. The results will be communicated to the patient by the dental surgeon
- Pregnant women: a blood pregnancy test will be carried out for women of reproductive age who do not have contraception. Results will be communicated to the patient by the dental surgeon
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.